Details
Stereochemistry | MIXED |
Molecular Formula | C24H33NO3 |
Molecular Weight | 383.5237 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=CC=CC3=CC=CC=C23
InChI
InChIKey=KBAFPSLPKGSANY-UHFFFAOYSA-N
InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. The drug act as a selective antagonist of 5-HT2 receptors. Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftoling, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax. Praxilene belongs to a group of medicines known as ‘metabolic activators’. These are used to treat different types of blood circulation problems. Praxilene allows the body to make better use of the oxygen in your blood. Praxilene is used to treat the following symptoms: cramp-like pains; cramps in legs at night; severe pain in r legs when people are resting (rest pain); pale or blue fingers or toes which get worse when it is cold; numbness, tingling or burning feelings in the fingers or toes (Raynaud’s syndrome or acrocyanosis); open sores on the legs or feet (trophic ulcers); poor circulation caused by diabetes (diabetic arteriopathy).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095200 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1369714 |
0.06 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Praxilene Approved UseUnknown Launch Date1.45186554E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Naftidrofuryl oxalate, nootropic effects on the scopolamine- and the basal forebrain lesion-induced amnesia in rats. | 1991 Aug |
|
Behavioral studies of the effects of moderate oligemic hypoxia caused by bilateral clamping of carotid arteries in mice. Impairment of spatial working memory. | 1998 Jul-Oct |
|
[Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. | 2001 Apr |
|
New treatment options in intermittent claudication: the US experience. | 2001 Apr |
|
Naftidrofuryl in the treatment of vascular dementia. | 2001 Dec |
|
Naftidrofuryl in quality of life (NIQOL). A Belgian study. | 2001 Dec |
|
[Intermittent claudication. Walking plus vasoactive drug treatment]. | 2001 Jul 5 |
|
[Deleterious cardiac effects of serotonin in myocardial ischemia: role of naftidrofuryl]. | 2001 Jun |
|
A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). | 2001 Mar |
|
Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents. | 2001 May |
|
Treatment alternatives for nocturnal leg cramps. | 2001 May 21 |
|
Pharmacotherapy of intermittent claudication. | 2001 Nov |
|
[Current EMNID survey on peripheral arterial occlusive disease]. | 2002 |
|
Effect of naftidrofuryl on intramuscular partial oxygen pressure (pO2) prior to, during and after physical load on the treadmill in apparently healthy subjects. | 2002 |
|
Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. | 2002 Aug |
|
Can claudication be improved with medication? | 2002 Dec |
|
Naftidrofuryl exerts antiserotonergic but no endothelin-receptor blocking effects in AS4.1 cells, juxtaglomerular cells and isolated perfused rat kidneys. | 2002 Jan |
|
Vitamin A metabolism is altered in brown Norway and long-Evans rats infused with naftidrofuryl or erythromycin intravenously. | 2002 Jul |
|
Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. | 2002 Mar |
|
[Application of prostaglandin E1 and Naftidrofuryl in combined treatment of purulent-necrotic complications of the diabetic foot syndrome]. | 2002 Nov-Dec |
|
Nocturnal leg cramps in older people. | 2002 Oct |
|
Characterization of the CNS effects of naftidrofuryl (Praxilène) by quantitative EEG and functional MRI: a study in healthy elderly subjects. | 2003 |
|
Raynaud's phenomenon (primary). | 2003 Jun |
|
Naftidrofuryl-induced liver injury. | 2003 Jun |
|
Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide. | 2003 Mar 1 |
|
[Evidence-based therapy of intermittent claudication]. | 2004 |
|
Drug treatment of intermittent claudication. | 2004 |
|
Calcium oxalate deposition in renal allografts: morphologic spectrum and clinical implications. | 2004 Aug |
|
[Secondary prevention and conservative therapy of obliterative arteriosclerosis]. | 2004 May 16 |
|
Naftidrofuryl: a review of its use in the treatment of intermittent claudication. | 2005 |
|
Pharmacokinetics of naftidrofuryl in patients with renal impairment. | 2005 |
|
Acral necrosis after inadequate excessive administration of bleomycin in a testicular cancer patient. | 2005 Jan |
|
Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. | 2005 Jun |
|
[Vasoactive agents and prostanoids in the therapy of PAD: facts, questions, disproven assumptions]. | 2006 Aug |
|
[Inpatient infusion treatment for acute tinnitus with and without adjuvant psychotherapeutic intervention. A comparison of psychological effectiveness]. | 2006 Oct |
|
Peripheral arterial disease in the elderly. | 2007 |
|
Naftidrofuryl for acute stroke. | 2007 Apr 18 |
|
A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. | 2007 Feb |
|
Prognostic indicators of management of sudden sensorineural hearing loss in an Asian hospital. | 2007 Jan |
|
[Idiopathic sudden sensorineural hearing loss. What's the appropriate management?]. | 2007 Oct |
|
Management of peripheral arterial disease in the elderly: focus on cilostazol. | 2008 |
|
Naftidrofuryl for intermittent claudication. | 2008 Apr 16 |
|
Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. | 2009 Jul |
|
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. | 2009 Mar 10 |
|
Pharmacologic therapy for intermittent claudication. | 2009 May |
|
Vasodilators and vasoactive substances for idiopathic sudden sensorineural hearing loss. | 2009 Oct 7 |
|
Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. | 2010 Feb 23 |
|
I suffer from frequent leg cramps and I've heard that quinine can help. Should I consider taking it? | 2010 Jun |
|
Silence of the limbs pharmacological symptomatic treatment of intermittent claudication. | 2010 May |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
The recommended dose is one or two capsules (100 mg naftidrofuryl oxalate) three times a day, for a minimum of three months
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7863151
After culture in a rat serum enriched with naftidrofuryl at concentration of 20 uM, we observed a protective effect of this drug toward the disruption of axonal microtubules by vinka alkaloids
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C04AX21
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
||
|
WHO-VATC |
QC04AX21
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
42H8PQ0NMJ
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
m7707
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB13588
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
Naftidrofuryl
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
SUB09130MIG
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
4417
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
250-572-2
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
2177
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
D009257
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
CHEMBL1620794
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
DTXSID3023344
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
31329-57-4
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
1870
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
100000084457
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
C87212
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | |||
|
7236
Created by
admin on Sat Dec 16 15:48:38 UTC 2023 , Edited by admin on Sat Dec 16 15:48:38 UTC 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)